CGT Manufacturing | cell and gene therapy

11 May 2020

Viral Aggregation in Downstream Processing of Lentiviral Vectors

Viral vectors are vehicles for delivery of therapeutic DNA in cell and...

17 Apr 2020

Quality-by-Design Approach to Manufacturing Cell and Gene Therapies

Implementation of a manufacturing process that assures a predefined qu...

29 Jan 2020

Induced Pluripotent Stem Cells – Understanding Reprogramming

Stemming (pun intended) from the fundamental question in developmental...

10 Jan 2020

Road to success: Understanding Good Laboratory Practice for cell and gene therapies

Good Laboratory Practice (GLP) studies are essential for generating no...

21 Nov 2019

What Are the Benefits of an Automated High-Throughput Screening Process for Custom Cell Culture Media Development?

We are often asked if culture media development can be customized at t...

30 Oct 2019

Five Steps to Ensure Your Cell and Gene Therapy Product Is GMP Compliant

When we think about cell and gene therapies (CGTs) what most often com...

30 Oct 2019

Considerations for the Use of Stable Producer Lines in the Manufacturing of Lentiviral Vectors

In an introductory post on lentiviral vector (LVV) manufacturing for c...

22 Oct 2019

How Can a Contract Development and Manufacturing Organization (CDMO) Advance a Cell & Gene Therapy Product?

Making the Decision to Engage a CDMO

MaRS Centre, West Tower
661 University Avenue, Suite 1002
Toronto, Ontario M5G 1M1 Canada
t: 416-978-3751
f: 416-978-1368

We wish to acknowledge this land on which CCRM operates. For thousands of years, it has been the traditional land of the Huron-Wendat, the Seneca, and the Mississaugas of the Credit. Today, this meeting place is still the home to many Indigenous people from across Turtle Island and we are grateful to have the opportunity to work on this land.